相关实验视频

Updated: Oct 2, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

用机器学习方法对突变亚型特定的LUAD中药物反应的广泛预测

Kegang Jia¹, Yawei Wang², Q I Cao³

¹Department of Thoracic Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.

Oncology research

|January 8, 2024

概括

这项研究确定了预测肺癌药物反应的关键基因和突变特征. 机器学习模型可以准确预测治疗的有效性,帮助针对非小细胞肺癌 (NSCLC) 的个性化药物.

科学领域:

基因组学和计算生物学
癌症治疗方法和药物发现
精准医学中的机器学习

背景情况:

肺腺癌 (LUAD) 是全球癌症死亡的主要原因,治疗失败通常是由药物耐药性驱动的.
瘤异质性,以多样化的遗传,表观遗传和表型细胞群体为特征,使治疗复杂化,并导致复发.
了解药物反应的分子驱动因素对于克服LUAD中耐药性至关重要.

研究的目的:

确定与非小细胞肺癌 (NSCLC) 药物反应相关的mRNA和突变特征.
开发和比较机器学习 (ML) 模型,以根据分子特征预测药物反应.
调查已识别的分子特征对LUAD亚型的预后影响.

主要方法:

利用癌症药物敏感性基因组学 (GDSC) 数据库对NSCLCmRNA表达,突变档案和药物敏感性数据.
采用ML算法,包括随机森林 (RF),人工神经网络 (ANN) 和支持矢量机器 (SVM) 进行响应预测.
验证了预测模型,并确定了特定药物反应的关键分子特征 (mRNA和突变).

主要成果:

在46种药物中确定了1564个基因和45个突变特征.
支持矢量机 (SVM) 实现了高准确度 (AUC 0.875) 预测使用特定基因和突变标志物的Afuresertib反应.
人工神经网络 (ANN) 在使用9个mRNA特征对Gefitinib反应预测表现强 (AUC为0.780).

结论:

机器学习有效地识别了在LUAD中预测药物反应的分子特征.
提出了一种基于ML的优先算法,用于预测NSCLC中各种治疗剂的药物疗效.
这些发现为开发向疗法和改善肺癌患者治疗策略提供了基础.

关键词:

药物耐药性药物耐药性药物耐药性肺部腺癌瘤是肺部腺癌.机器学习是机器学习.分子特征分子特征.个性化治疗个性化治疗

更多相关视频

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...